Vol. 17/No. 4 | Oncology Live®

February 16, 2016

Although metastatic breast cancer remains incurable for most women, recent research offers important new guidance for clinicians managing patients across the spectrum of advanced disease.

February 16, 2016

Experts in the field assert that the path forward requires a paradigm shift toward integrative analyses that encompass multiple classes of genomic aberrations and consensus classification of CRC based on genomic data to facilitate more effective management of this disease.

February 15, 2016

Separating hype from hope has often been problematic when developments that may lead to advances in the oncology field enter the public domain. The mapping of the human genome and the ability to characterize mutations associated with cancer have spawned one of those waves of excess promises.

February 15, 2016

Epigenetic therapy has emerged as a novel approach, not necessarily by killing cancer cells, but perhaps by altering the network of chemical changes that affect the DNA/chromatin within cancer cells.

February 12, 2016

We now have a better understanding of the sequence of events, particularly regarding the timing of these mutations, their impact, and some of the factors involved that might cause them.

February 12, 2016

Changes are brewing again in the direct-to-consumer genetic testing industry including developments with the potential to affect the public in the oncology field.

February 11, 2016

Although the goals of quality-care and value-based oncology initiatives are legitimate and laudable, some of the assertions should be examined more closely.

February 11, 2016

The role of immunotherapy is emerging as an effective, and in some cases, dramatic treatment in the non-small cell lung cancer landscape.

February 11, 2016

Manish A. Shah, MD, discusses the BRIGHTER trial, which is investigated BBI608 as a second-line treatment for patients with gastric and gastroesophageal junction cancer who already have undergone platinum and fluoropyrimidine-based chemotherapy.